GlassScriptPhysician profile
Julia Sabetta
NPI 1255356184
$3,264.32
in general payments reported to CMS, 2019-2025
17 companies · $535 in 2025
The $535 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $266 · 2021: $25.94 · 2022: $163 · 2023: $1,225 · 2024: $798 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,558.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $829.43 | 2023-2025 | |
| Galderma Laboratories, L.P. | $476.51 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $421.21 | 2022-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $354.03 | 2023-2025 | |
| Lilly USA, LLC | $215.35 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $214.61 | 2022-2025 | Opzelura |
| Allergan, INC. | $189.26 | 2019-2020 | |
| Janssen Biotech, INC. | $139.38 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Solta Medical, A Division of Bausch Health US, LLC | $108.53 | 2019 | |
| Biofrontera INC. | $68.77 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Arcutis Biotherapeutics, INC. | $61.07 | 2023-2024 | Zoryve |
| Sun Pharmaceutical Industries INC. | $57.32 | 2023-2025 | Winlevi, Absorica Ld, Ilumya |
| Merz North America, INC. | $42.40 | 2023 | |
| Blueprint Medicines Corporation | $28.82 | 2023 | Ayvakit |
| Mayne Pharma Commercial LLC | $22.94 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.40 | 2025 | Spevigo |
| Strata Skin Sciences, INC. | $14.29 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Sabetta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.